{
    "clinical_study": {
        "@rank": "52046", 
        "arm_group": {
            "arm_group_label": "Avastin + Xeloda", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus\n      intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The\n      anticipated time on study treatment is 3-12 months."
        }, 
        "brief_title": "A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer", 
        "completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "condition": "Liver Cancer", 
        "condition_browse": {
            "mesh_term": "Liver Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients >=18 years of age;\n\n          -  advanced or metastatic liver cancer;\n\n          -  >=1 measurable lesion.\n\n        Exclusion Criteria:\n\n          -  current radiotherapy, chemotherapy, or other experimental therapies;\n\n          -  prior cytotoxic chemotherapy;\n\n          -  major surgery, open biopsy, or traumatic injury within 28 days of study entry;\n\n          -  history of a malignancy during the last 5 years, other than cutaneous basal cell\n             cancer or in situ cervical cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013830", 
            "org_study_id": "ML18469"
        }, 
        "intervention": [
            {
                "arm_group_label": "Avastin + Xeloda", 
                "description": "7.5mg/kg iv on day 1 of each 3 week cycle.", 
                "intervention_name": "bevacizumab [Avastin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Avastin + Xeloda", 
                "description": "1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.", 
                "intervention_name": "capecitabine [Xeloda]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "zip": "3181"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kueishan", 
                        "country": "Taiwan", 
                        "zip": "333"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "00112"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "114"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "106"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Hong Kong", 
                "Singapore", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Therapeutic Goods Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Objective response rate", 
            "safety_issue": "No", 
            "time_frame": "18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2005", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}